共 50 条
- [41] Phase I study of intravenous PSC-833 and doxorubicin: Reversal of multidrug resistanceJAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (02): : 220 - 230Minami, HOhtsu, TFujii, HIgarashi, TItoh, KUchiyama-Kokubu, NAizawa, TWatanabe, TUda, YTanigawara, YSasaki, Y
- [42] A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.BLOOD, 1997, 90 (10) : 2256 - 2256Lee, EGeorge, SCaligiuri, MDodge, RSmith, RSzatrowski, TSchiffer, C
- [43] The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemiaLeukemia, 1998, 12 : 912 - 920ML Den BoerR PietersKM KazemierGE Janka-SchaubG HenzeAJP Veerman
- [44] ACLARUBICIN IN THE TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA REFRACTORY TO TREATMENT WITH DAUNORUBICIN AND CYTARABINE - A PHASE-II TRIALCANCER TREATMENT REPORTS, 1984, 68 (10): : 1233 - 1238PEDERSENBJERGAARD, JBRINCKER, HELLEGAARD, JDRIVSHOLM, AFREUND, LJENSEN, KBJENSEN, MKNISSEN, NI
- [45] Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2831 - 2839Lee, EJGeorge, SLCaligiuri, MSzatrowski, TPPowell, BLLemke, SDodge, RKSmith, RBaer, MSchiffer, CA
- [46] A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumorsCLINICAL CANCER RESEARCH, 1997, 3 (11) : 2005 - 2015Giaccone, GLinn, SCWelink, JCatimel, GStieltjes, HvanderVijgh, WJFEeltink, CVermorken, JBPinedo, HM
- [47] A PHASE-III TRIAL COMPARING IDARUBICIN AND DAUNORUBICIN IN COMBINATION WITH CYTARABINE IN ACUTE MYELOGENOUS LEUKEMIA - A SOUTHEASTERN CANCER STUDY-GROUP STUDYJOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1103 - 1111VOGLER, WRVELEZGARCIA, EWEINER, RSFLAUM, MABARTOLUCCI, AAOMURA, GAGERBER, MCBANKS, PLC
- [48] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)BLOOD, 2017, 130Zeidner, Joshua F.Vincent, Benjamin G.Ivanova, AnastasiaFoster, MatthewCoombs, Catherine C.Jamieson, KatarzynaVan Deventer, HendrikScibilia, RichardBlanchard, LauraFrank, CassiopeiaGallagher, SeanMatson, MelissaPepin, KatherineVaught, LoriVogler, NancyGojo, IvanaLuznik, LeoSerody, Jonathan S.
- [49] The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBLOOD, 2005, 106 (08) : 2646 - 2654van der Holt, BLöwenberg, BBurnett, AKKnauf, WUShepherd, JPiccaluga, PPOssenkoppele, GJVerhoef, GEGFerrant, ACrump, MSelleslag, DTheobald, MFey, MFVellenga, EDugan, MSonneveld, P
- [50] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II studyInvestigational New Drugs, 1999, 17 : 89 - 95Norbert VeyHagop KantarjianMiloslav BeranSusan O'BrienJorge CortesCharles KollerElihu Estey